Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic (PAPESCO-19)


Institut Cancerologie de l'Ouest






Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff

Study type


Funder types




Details and patient eligibility


The Covid-19 has, in a few weeks, made the world tremble: the number of deaths (mainly elderly and / or co-morbid) continues to increase, the confinement causes the collapsing of the economy and the decline of relationships inter-human. The data are too fragmented and the disease too recent to know its repercussions on the 3 million French people who have or have had cancer. The investigators would like, in 3 populations: \* patients in treatment, \* or in follow-up and \* health personnel, to constitute a large prospective and longitudinal database of data: i / serological: humoral response, test performance, monitoring of serum immunoglobulin levels , reinfection threshold,...; ii / clinical: incidence, severity, mortality and their favorable factors impact of cancer treatment on Covid-19 infection and modification of the quality of oncological care in the context. In parallel, on a more limited sample of establishments, it will be : \* appreciate the economic and functional repercussions, \* will try to find out about the infection modalities in patients and health personnel and \* will appreciate the levels of anxiety and depression to which health staff are subject.

Full description

The participation of the study will be offered to each patient when they will come to the centre (by oncologist, radiotherapist, surgeon, ...). For the health staff, the information can be delivered through different channels (posting, mail, mail, intranet...). This will make the informed consent available to all staff. Participation will be voluntary: staff who have read the information note and wish to participate in the study will have to register on the "PAPESCO-01" screening schedule, during which they will sign their consent with the occupational physician (or anyone delegated by occupational medicine), then have their first sample and complete the various questionnaires. The screening of the patients and of the health staff will be done by 2 or 3 techniques depending of the results. The first technic is a blood test done at M0 (inclusion), M3, M6, M9 and M12 and on demand in case of Covid-19 symptoms (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens (only at M0)). The second technic nasal swab test (RT-PCR) is done only in case of symptoms (whatever the result of the minute test is) for the hospitalized patients. The results of the tests realised in town will be get back through the questionnaires. The third technic is the questionnaires to the patients and the health staff.


2,307 patients




18+ years old


Accepts Healthy Volunteers

Inclusion criteria

  • Age >= 18 years
  • Population in Cancer centres responding to one of these 3 definitions: patients having a treatment in process, patients under surveillance ( having completed their treatment for more than a year), health staff.
  • Subjects who may or may not have had an infection compatible or proven with a Covid-19 infection.
  • Information to the participants and signature of the informed consent.
  • Subject affiliated with a social insurance

Exclusion criteria

  • Refusal of consent
  • Patients who are unable to consent or have a psychiatric history
  • Inability to submit to the medical follow-up of the study for geographical, social or psychological reasons
  • Person under guardianship or protection of vulnerable adults
  • Person deprived of liberty by a judicial or administrative decision

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

2,307 participants in 1 patient group

Diagnostic test for SARS-Cov2 for patients and health staff
Experimental group
Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens) Nasal swab test (only if the patient has symptoms) Questionnaires
Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems